Surgical Therapy and Survival in HCC/ C.F. Zhang et al.

Surgical Therapy and Survival in Young Patients With Stage I-II Hepatocellular Carcinoma: A Retrospective Cohort Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04820712

Enrollment

664

Registered

2021-03-29

Start date

2020-09-01

Completion date

2021-01-01

Last updated

2021-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma, Surgery

Brief summary

This study utilizes a new method to explore compare the overall survival (OS) and cancer-specific survival (CSS) in patients aged 18-45 years with stage I-II HCC who underwent different types of surgery. The SEER database, which is one of the most comprehensive and authoritative databases concerning cancer, was used to estimate the survival benefit of patients who underwent local tumor destruction (LTD), wedge or segmental resection (WSR), lobectomy resection (LR), liver transplantation (LT), or non-surgery. This study discovered surgery offered a survival benefit compared with non-surgery for young patients with stage I-II HCC. Furtherly, LT is associated with superior survival than WSR, LR and LTD in those patients. Our results facilitate the selection of surgical strategies.

Detailed description

The SEER data contain no identifiers and are publicly available for studies of cancer-based epidemiology and survival analysis. Therefore, the current study was deemed to be exempt from Institutional Review Board approval and the need for informed consent was waived. The submitted magazine requires registration on the website, so this operation is needed.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 45 Years

Healthy volunteers

Inclusion criteria

1. Patients were diagnosed with colorectal cancer only; 2. Patients with simultaneous metastasis of liver and lung cancer cells; 3. Patients without metastasis resection; 4. whether they underwent palliative primary tumor resection was known; 5. Their cause of death was known; 6. Their survival time were known and greater than 0 month; 7. Patients were diagnosed with microscopic confirmation.

Exclusion criteria

* No

Design outcomes

Primary

Measure	Time frame	Description
Overall survival	2004.1.1-2013.12.31	Overall survival was defined as the duration between the surgery and death or the last follow-up

Secondary

Measure	Time frame	Description
Cancer-specific survival	2004.1.1-2013.12.31	Cancer-specific survival was defined as the period between the surgery and death due to cancer to reduce the impact of life-threatening comorbidities.

Countries

China

Outcome results